Advanced

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer's disease

Silajdzic, Edina LU ; Björkqvist, Maria LU and Hansson, Oskar LU (2015) In BMC Neurology 15.
Abstract
Background: Phosphorylcholine is one of the major epitopes of oxidised low density lipoprotein. Low levels of IgM antibodies against phosphorylcholine (anti-PC) are associated with development of myocardial infarction and stroke. It has been shown that patients with Alzheimer's disease and other dementias have significantly lower serum anti-PC levels compared to controls, suggesting that low levels of atheroprotective anti-PC may play a role in AD and dementia. Methods: We quantified levels of anti-PC levels using an ELISA in plasma from 176 controls, 125 patients with Alzheimer's disease, 19 patients with vascular dementia and 63 patients with other dementias. Results: We observed similar plasma anti-PC levels in controls, patients with... (More)
Background: Phosphorylcholine is one of the major epitopes of oxidised low density lipoprotein. Low levels of IgM antibodies against phosphorylcholine (anti-PC) are associated with development of myocardial infarction and stroke. It has been shown that patients with Alzheimer's disease and other dementias have significantly lower serum anti-PC levels compared to controls, suggesting that low levels of atheroprotective anti-PC may play a role in AD and dementia. Methods: We quantified levels of anti-PC levels using an ELISA in plasma from 176 controls, 125 patients with Alzheimer's disease, 19 patients with vascular dementia and 63 patients with other dementias. Results: We observed similar plasma anti-PC levels in controls, patients with Alzheimer's disease, and other dementias. Conclusions: Our data suggests that anti-PC is not useful as a biomarker for Alzheimer's disease. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Anti-phosphorylcholine, Alzheimer's disease, Dementia, Biomarker
in
BMC Neurology
volume
15
publisher
BioMed Central
external identifiers
  • wos:000349352800001
  • scopus:84924086826
ISSN
1471-2377
DOI
10.1186/s12883-015-0260-1
language
English
LU publication?
yes
id
f62a3127-e2b5-4205-85ee-bb5c61df8f21 (old id 5186101)
date added to LUP
2015-04-01 07:34:32
date last changed
2017-10-01 04:16:10
@article{f62a3127-e2b5-4205-85ee-bb5c61df8f21,
  abstract     = {Background: Phosphorylcholine is one of the major epitopes of oxidised low density lipoprotein. Low levels of IgM antibodies against phosphorylcholine (anti-PC) are associated with development of myocardial infarction and stroke. It has been shown that patients with Alzheimer's disease and other dementias have significantly lower serum anti-PC levels compared to controls, suggesting that low levels of atheroprotective anti-PC may play a role in AD and dementia. Methods: We quantified levels of anti-PC levels using an ELISA in plasma from 176 controls, 125 patients with Alzheimer's disease, 19 patients with vascular dementia and 63 patients with other dementias. Results: We observed similar plasma anti-PC levels in controls, patients with Alzheimer's disease, and other dementias. Conclusions: Our data suggests that anti-PC is not useful as a biomarker for Alzheimer's disease.},
  articleno    = {8},
  author       = {Silajdzic, Edina and Björkqvist, Maria and Hansson, Oskar},
  issn         = {1471-2377},
  keyword      = {Anti-phosphorylcholine,Alzheimer's disease,Dementia,Biomarker},
  language     = {eng},
  publisher    = {BioMed Central},
  series       = {BMC Neurology},
  title        = {Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer's disease},
  url          = {http://dx.doi.org/10.1186/s12883-015-0260-1},
  volume       = {15},
  year         = {2015},
}